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Abstract
Background: Severe cardiotoxicity is a documented, but very unusual side-effect of intravenous
5-fluorouracil therapy. The mechanism producing cardiotoxicity is poorly understood.
Case presentation: A case of 5-fluorouracil-induced cardiotoxicity, possibly due to coronary
artery spasm, and mimicking acute anterolateral myocardial infarction is presented and discussed.
Electrocardiographs highlighting the severity of the presentation are included in the report along
with coronary angiograms demonstrating the absence of significant coronary atherosclerosis.
Conclusion: Severe 5-fluorouracil-induced cardiotoxicity is rare, but can be severe and may mimic
acute myocardial infarction, leading to diagnostic and therapeutic dilemmas. Readministration of 5-
fluorouracil is not advised following an episode of cardiotoxicity.
Background
Severe 5-fluorouracil (5-FU) cardiotoxicity is unusual,
but documented. Intravenous infusion of the drug has
been documented to cause angina [1], myocardial infarc-
tion [2], acute pulmonary oedema [3], supraventricular
and ventricular arrythymias [4], and sudden death [1].
Although the incidence of angina related to application
of 5-FU is between 1.2 and 18% [5], severe or life-threat-
ening cardiotoxicity, defined as ST segment elevation on
electrocardiogram or ventricular arrythymias, is much
rarer, with an incidence of about 0.55% [6].
The mechanisms involved in 5-FU cardiotoxicity have
not yet been fully identified, but coronary artery spasm
has been identified as one possibility.
The case discussed outlines the presentation of a gentle-
man receiving 5-FU therapy to our cardiology unit with
chest pain and electrocardiograph changes consistent
with acute anterolateral myocardial infarction. Subse-
quent management and investigation, and the rationale
to our final conclusion that his presentation was second-
ary to 5-FU cardiotoxicity are also discussed.
Case Presentation
A 77 year old man was transferred from an oncology unit.
He had been diagnosed with squamous cell carcinoma of
the anus and was admitted for combined radiotherapy
and chemotherapy with 5-fluorouracil and mitomycin C.
On the fourth day of intravenous therapy with 5-fluorou-
racil he developed central chest pain radiating into the
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left arm and associated with nausea and sweating. An
electrocardiogram showed ST segment elevation in leads
I, aVL and V6 and hyperacute T wave changes in leads
V3-V6 (figure 1). The episode lasted thirty minutes with
discontinuation of the 5-fluorouracil infusion and ad-
ministration of sublingual glyceryl trinitrate producing
both symptomatic relief and resolution of the electrocar-
diographic changes (figure 2).
Six hours later, he had a second episode of chest pain as-
sociated with similar electrocardiographic changes. On
this occasion, he was treated with aspirin 300 mg and in-
travenous diamorphine, again resulting in resolution of
the pain and the changes on the electrocardiogram with-
in twenty minutes. A presumptive diagnosis of coronary
artery spasm was made and transfer to our coronary care
unit was arranged for further management.
He was stable on transfer and pain-free. Cardiovascular
examination was normal. He was treated with oral ni-
trates and calcium channel antagonists. Serial serum
cardiac enzymes and serum troponin I levels were nor-
mal. Past medical history included a diagnosis of myo-
cardial infarction seven years previously. There was no
history of angina. Maturity onset diabetes mellitus was
diagnosed within the past year. He had no history of hy-
pertension, had never smoked tobacco and had no family
history of ischaemic heart disease. Serum cholesterol
was 4.36 mmol/.
There were no further episodes of chest pain and he pro-
ceeded to coronary angiography. This revealed minor ir-
regularity in the left anterior descending artery at the
origin of the first diagonal branch. The left main coro-
nary, left circumflex and right coronary arteries were
normal (Figures 3 & 4). Left ventriculography showed
hypokinesis of the anterior wall. The relative normality
of the coronary arteries supported a diagnosis of 5-fluor-
ouracil-induced coronary artery spasm. The history of a
myocardial infarction in his past medical history in light
of the findings at coronary angiography may indicate an
underlying tendency to coronary vasospasm in this man.
He was transferred back to the oncology unit for further
management of his carcinoma. It was advised that if fur-
ther chemotherapy was indicated, then an agent other
than 5-FU should be used.
Discussion
We have presented a case of severe cardiotoxicity occur-
ring in a gentleman receiving 5-FU chemotherapy for sq-
uamous cell carcinoma of the anus. The case is unusual
in that the presentation mimicked an acute myocardial
infarction, with ST segment elevation noted on the elec-
trocardiogram.
Coronary artery spasm has been postulated as a possible
mechanism for cardiotoxicity, based mainly on the find-
ing of clinical and electrocardiographic evidence of re-
versible ischaemic heart disease in the absence of
coronary atherosclerosis on angiography. Furthermore,
coronary artery spasm has been documented angio-
graphically following intravenous 5-FU administration
Figure 1
ECG taken at time of chest pain
Figure 2
ECG after pain resolved
Figure 3
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[6], and prophylaxis with calcium channel antagonists
has been successfully employed in preventing recurrence
[7].
An alternative suggested mechanism is that 5-FU may
cause metabolic changes producing hypoxia within myo-
cardial cells, therefore imitating ischaemic heart disease
[8].
Repeated exposure to 5-FU following an episode of car-
diotoxicity carries a risk of relapse of between 82 and
100% of case and therefore it is advised that the drug
should not be re-administered in this group of patients
[9].
Note
Written consent for publication of the case was obtained
from the patient
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Right coronary angiogram